Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.38 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL579460 | 0.90 | ALDH1A1 (0.53) | ALDH1A1KMT2AMAPTEHMT2EHMT1 | |
| SCHEMBL2743794 | 0.88 | ALDH1A1 (0.56) | ALDH1A1KMT2AMAPTLMNARAB9A | |
| SCHEMBL17139516 | 0.84 | ALDH1A1 (0.33) | ALDH1A1KMT2AMAPTEHMT2EHMT1 | |
| SCHEMBL110223 | 0.82 | ALDH1A1 (0.46) | ALDH1A1KMT2AMAPTEHMT2EHMT1 | |
| SCHEMBL20601972 | 0.80 | HDAC1 (0.36) | ALDH1A1KMT2AMAPTEHMT2EHMT1 | |
| SCHEMBL18022125 | 0.79 | ALDH1A1 (0.45) | ALDH1A1KMT2AMAPTEHMT2EHMT1 | |
| SCHEMBL23512422 | 0.78 | ALDH1A1 (0.51) | ALDH1A1KMT2AMAPTEHMT2EHMT1 | |
| SCHEMBL10581045 | 0.77 | LMNA (0.53) | ALDH1A1KMT2AMAPTEHMT2EHMT1 | |
| SCHEMBL906682 | 0.76 | ALDH1A1 (0.41) | ALDH1A1KMT2AMAPTEHMT2EHMT1 | |
| SCHEMBL18805587 | 0.76 | LMNA (0.62) | ALDH1A1KMT2AMAPTEHMT2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178793-A1 | NUCLEOTIDE-COCHLEATE COMPOSITIONS AND METHODS OF USE | BIODELIVERY SCIENCES INTERNATIONAL, INC. (US) | 2012-07-12 | — | — | US | claimed |
| US-5000960-A | Using bifunctional agent to form disulfide bond | MICRO-PAK, INC. (US) | 1991-03-19 | — | — | US | claimed |
| US-20120178793-A1 | NUCLEOTIDE-COCHLEATE COMPOSITIONS AND METHODS OF USE | BIODELIVERY SCIENCES INTERNATIONAL, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8110217-B2 | Sphingomyelin liposomes for the treatment of hyperactive bladder disorders | UNIVERSITY OF PITTSBURGH (US) | 2012-02-07 | — | — | US | disclosed |
| US-20110269942-A1 | ANTIBODIES MODIFIED WITH HYDROPHOBIC MOLECULE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-11-03 | — | — | US | disclosed |
| US-20100209490-A1 | IMMUNOLIPOSOME INDUCING APOPTOSIS INTO CELL EXPRESSING DEATH DOMAIN-CONTAINING RECEPTOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2184355-A1 | ANTIBODY MODIFIED WITH HYDROPHOBIC MOLECULE | Daiichi Sankyo Company, Limited (JP) | 2010-05-12 | — | — | EP | disclosed |
| EP-2177230-A1 | IMMUNOLIPOSOME INDUCING APOPTOSIS INTO CELL EXPRESSING DEATH DOMAIN-CONTAINING RECEPTOR | Daiichi Sankyo Company, Limited (JP) | 2010-04-21 | — | — | EP | disclosed |
| US-20070122466-A1 | Sphingomyelin liposomes for the treatment of hyperactive bladder disorders | UNIVERSITY OF PITTSBURGH (US) | 2007-05-31 | — | — | US | disclosed |
| US-20060029656-A1 | Replacement enzyme cochleates | BIODELIVERY SCIENCES INTERNATIONAL, INC. (US) | 2006-02-09 | — | — | US | disclosed |
| US-20050220886-A1 | Modulators of the Notch signalling pathway and uses thereof in medical treatment | CELLDEX THERAPEUTICS LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| US-5623055-A | Phenylboronic acid complexes derived from aminosalicylic acid for bioconjugate preparation | PROLINX, INC. (US) | 1997-04-22 | — | — | US | disclosed |
| US-5594111-A | Phenylboronic acid complexes for bioconjugate preparation | PROLINX, INC. (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0741734-A1 | PHENYLBORONIC ACID COMPLEXES | PROLINX, INC. (US) | 1996-11-13 | — | — | EP | disclosed |
| US-5474765-A | Drug delivery; heparin/steroid conjugates; selectively hydrolyzable linkage e.g, an acid labile or enzyme-sensitive bond; angiogenesis inhibitors; anticarcinogenic,-arthritic and diabetic agents | UT SW MEDICAL CTR AT DALLAS (US) | 1995-12-12 | — | — | US | disclosed |
| EP-0683397-A1 | REAGENT FOR IMMUNOAGGLUTINATION AND IMMUNOANALYTICAL METHOD | NISSUI PHARMACEUTICAL CO., LTD. (JP) | 1995-11-22 | — | — | EP | disclosed |
| WO-1995020591-A1 | PHENYLBORONIC ACID COMPLEXES | PROLINX, INC. (US) | 1995-08-03 | — | — | WO | disclosed |
| EP-0632728-A1 | PREPARATION AND USE OF POLYANIONIC POLYMER-BASED CONJUGATES TARGETED TO VASCULAR ENDOTHELIAL CELLS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1995-01-11 | — | — | EP | disclosed |
| WO-1993018793-A1 | PREPARATION AND USE OF POLYANIONIC POLYMER-BASED CONJUGATES TARGETED TO VASCULAR ENDOTHELIAL CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-09-30 | — | — | WO | disclosed |
| US-4948590-A | Avidin or streptavidin conjugated liposomes | YALE UNIVERSITY (US) | 1990-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178793-A1 | NUCLEOTIDE-COCHLEATE COMPOSITIONS AND METHODS OF USE | NUDT1, NT5E, SLC29A1 | ALDH1A1 3241/4885KMT2A 2755/4885MAPT 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.